Fluoroquinolones and broad spectrum antibiotics are expected to lead sales growth of all antibiotics in a global market that will generate revenues of $58,798.1 million [sic] by year 2027. The fluoroquinolone segment, in a study by Research Dive, is expected to garner the highest revenue of all, reaching $10,143.1 million in sales by 2027, compared to $6,823.1 million in 2019. North America is predicted to dominate antibiotic sales due to higher prescribing among other factors. Researchers said the high growth of fluoroquinolone prescribing is because they are seen as “extremely effective” and that they enjoy a “large volume of distribution.” As a result, we can expect to see greater numbers of patients worldwide experiencing adverse events.